China: China’s New Anti-Corruption Policies in the Health Care Industry

Last Updated: 9 January 2014
Article by Lester Ross and Kenneth Zhou

On December 26 and 25, 2013, respectively, China's National Health and Family Planning Commission (NHFPC) promulgated two circulars, Circular [2013] No. 49 (Circular 49) and Circular [2013] No. 50 (Circular 50). Circular 49, issued by NHFPC's Chinese Medicine Management Bureau, provides comprehensive anti-corruption compliance requirements to be observed by hospitals and physicians, and Circular 50 establishes a "blacklist" system on pharmaceutical and medical device providers.
 
Circular 49 re-emphasizes the importance of compliance with anti-corruption rules and specifies "nine prohibitions" applicable to all hospitals, medical institutions and their employees in China. The fact that it was issued by the Chinese Medicine Management Bureau, rather than NHFPC as a whole, ought not necessarily be construed to limit its application to practitioners of Traditional Chinese Medicine (TCM) as Circular 49 is expressly tied to Central Party policy.  
 
The "nine prohibitions" are:

  • linking physicians' individual income with income generated from the sale of drugs or the provision of clinical services. Medical institutions are prohibited from assigning revenue targets to their departments and determining salaries or bonuses of individual physicians based on income generated from the sale of drugs or provision of medical examination services.
     
  • giving commissions to individual physicians based on the value of drugs prescribed or clinical services provided. Physicians are also prohibited from receiving commissions for referring patients for diagnostic tests, treatment, physical examinations or the purchase of drugs.
     
  • illegal fees. Medical institutions are prohibited from charging additional fees or raising fee standards beyond what is permissible under State drugs or clinical services policies.
     
  • accepting improper donations. Individuals in medical institutions are prohibited from accepting donations from companies. Medical institutions are prohibited from accepting donations under conditions that impede fair competition or otherwise affect procurement decisions.
     
  • participating in promotional activities or illegal health care advertisements. Medical institutions and their personnel are prohibited from participating in marketing and promotional activities related to pharmaceutical products, food or health care products. They are also barred from illegally disclosing the identities or private information of patients.
     
  • compiling statistical data for commercial purposes. Medical institutions are prohibited from compiling statistics on the quantities of drugs or medical devices purchased by individual physicians for non-medical purposes. Medical institutions are prohibited from providing conveniences to marketing personnel of pharmaceutical or medical device companies in calculating value-based commissions.
     
  • private procurement of medical products. Personnel of medical institutions are prohibited from procuring, selling or using medical products through private channels.
     
  • accepting commissions. Personnel of medical institutions are prohibited from accepting commissions or kickbacks in any form or otherwise participating in entertainment activities organized by their business counterparties.
     
  • accepting "red envelopes" from patients or their families and friends. 

Any violation of the above "nine prohibitions" is subject to disciplinary measures, including warning, demotion, reduction in compensation, suspension or cancellation of licenses. If a violation constitutes a crime, criminal liability will be pursued.
 
Circular 49 regulates the conduct of hospitals and their personnel. Compared to other rules and regulations, Circular 49 sets out more detailed guidelines on compliance conduct and requires that hospitals and medical institutions abolish certain existing practices which induce or constitute corruption. 
 
By contrast, Circular 50 regulates the conduct of pharmaceutical/medical device companies and their respective personnel by establishing a "blacklist" system that supersedes an earlier 2007 regulation which had proven ineffective.  
 
Circular 50 provides that relevant health departments at the provincial level shall establish a blacklist system to record companies and their personnel who are found to have engaged in bribery. 
 
A company and/or its individuals shall be put on the blacklist under any of the following circumstances:

  • conviction by a court for a crime of bribery, or conviction without criminal liability for minor bribery violations;
     
  • engaging in a crime of bribery for which the procuratorate decides not to pursue criminal charges;
     
  • investigation and penalization by Party disciplinary authorities based on the charge of bribery;
     
  • penalization by a local finance bureau, administration for industry and commerce (AIC) or food and drug administration (FDA) based on the charge of bribery; or
     
  • catch-all other circumstances provided under laws and regulations.

Simply put, if a drug or medical device company has engaged in commercial bribery which amounts to a crime, the company (and/or its relevant personnel) faces blacklisting even if criminal liability is not pursued. Even if conduct does not constitute the crime of bribery, a violation of administrative regulations for which the enforcement agency decides to pursue administrative liability will still subject to the company to the blacklist. Instances in which criminal prosecution is not pursued, the Party rather than a government body imposes penalties, or the vague catch-all provision is applied can result in imposition of the blacklist.     
 
The consequences of being blacklisted is serious under Circular 50. The blacklist is administered by relevant health departments at the provincial level. Once a company is blacklisted, public hospitals and other hospitals receiving State funding in the province concerned will be barred from purchasing from the company for two years thereafter. If a company is blacklisted two or more times in a five-year period, all public hospitals and other hospitals receiving State funding throughout the country will be barred from purchasing from the company.    
  
Under Circular 50, a hearing is to be held before a company is blacklisted. Different enforcement agencies, including the Party's disciplinary agencies, local finance bureaus, AICs, commerce bureaus, FDAs and other agencies, are required to coordinate with each other in the investigation of commercial bribery cases. 

Responsible officials of medical institutions, drug procurement personnel and physicians who accept gifts or other benefits from vendors or their representatives also face sanctions.

Circular 50 takes effect on March 1, 2014. However, it is unclear whether the circular will apply retroactively if the sanctions are meted out for conduct occurring before such date.
 
The promulgation of the two circulars during the New Year holiday period indicates that China is determined to intensify its efforts to crack down on corruption activities in the health care industry. The two circulars constitute renewed government efforts to systematically regulate the conduct of all players in the health care industry after the central government's launch of a nationwide campaign against commercial bribery in the health care industry in August 2013 following the GSK bribery case. 
 
For multinationals engaged in the health care business in China, Circular 50 is expected to play a critical role in the future. While the concept of a blacklist system was embodied in some earlier regulations, such system was not strictly implemented in the past. 
 
With more detailed implementing procedures and conditions under Circular 50 expected, it is apparent that the Chinese government will enforce the system seriously in the future. 
 
Compared to bribery investigations and charges which constitute a crime, local AIC administrative investigations of commercial bribery which does not rise to the level of a crime are much more common in practice. Many multinationals have been subject to such administrative investigations since the launch of the nationwide campaign to crack down on bribery following the GSK case. 
 
If such investigation results in administrative penalties, companies upon being penalized are at risk of being blacklisted under Circular 50, which will result in serious disruption to their businesses because of the ban on future procurement by public hospitals, which account for the majority of hospitals in China. 
 
Unlike the United States and some other foreign jurisdictions where a settlement with the law enforcement agencies to avoid formal charges is possible, China at present does not have a formal "settlement" process which further narrows the options for multinationals being investigated. It is therefore vitally important to tighten internal compliance policies and to craft appropriate strategies when facing such investigations.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions